My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
About Us
Plans & Pricing
Welcome

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Moderna (MRNA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacira Pharmaceuticals (PCRXResearch Report) and Moderna (MRNAResearch Report).

Pacira Pharmaceuticals (PCRX)

In a report released yesterday, David Steinberg from Jefferies maintained a Buy rating on Pacira Pharmaceuticals, with a price target of $85.00. The company’s shares closed last Wednesday at $55.18.

According to TipRanks.com, Steinberg is a 4-star analyst with an average return of 9.1% and a 49.5% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Horizon Therapeutics, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Strong Buy with an average price target of $83.00, a 51.6% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $80.00 price target.

See today’s analyst top recommended stocks >>

Moderna (MRNA)

Jefferies analyst Michael Yee maintained a Hold rating on Moderna yesterday and set a price target of $485.00. The company’s shares closed last Wednesday at $434.46, close to its 52-week high of $497.49.

According to TipRanks.com, Yee is a 4-star analyst with an average return of 9.3% and a 48.5% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Allogene Therapeutics, and Sigilon Therapeutics.

Currently, the analyst consensus on Moderna is a Hold with an average price target of $328.00, implying a -23.3% downside from current levels. In a report issued on September 7, Morgan Stanley also maintained a Hold rating on the stock with a $337.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PCRX: